Any current/future new fundraising through debt or equity?

The transcript provided does not mention any current or planned fundraising through debt or equity. There is no discussion or indication from management about raising funds via capital markets or loans. The focus of the call was primarily on operational performance, project updates (benzene derivatives), government incentives, and financial results. No mention of new fundraising activities or plans to raise capital was made during the Q&A or management commentary. The management discussed interest and depreciation costs related to the benzene derivatives project, but no new financing announcem

Any current/future capex/capital investment/strategic investment?

The company has invested in the Saykha Greenfield benzene downstream project, a strategic expansion into specialty chemicals beyond its core dye stuff and dye intermediates business. This Saykha project recently achieved required quality norms and is in the process of obtaining customer certifications, especially targeting the pharmaceutical industry. Production and revenue contribution from this benzene derivatives project is expected to ramp up significantly starting Q4 FY25, with major volume increases thereafter. Interest and depreciation related to this project increased overheads, indica

Future growth expectations in sales/revenue/volumes?

Benzene derivatives project expected to contribute significantly from Q4 FY25, with revenue of ~Rs. 320 crore at 13%-14% EBITDA once at maximum capacity. Production volume for benzene derivatives targeted to reach over 50% utilization by January FY26, ramping up further thereafter. Dye intermediates division showing volume growth and better realizations; expected to deliver improved performance going forward. Chlor-Alkali business anticipating further volume growth driven by increased chlorine consumption; prices improving. Overall company revenue growth of 27% YoY in H1 FY25, led by volume im

Future growth expectations in earnings/operating earnings/profits/EPS?

Benzene derivatives project is expected to significantly contribute starting Q4 FY25, with full ramp-up by FY26, targeting Rs. 320 crores topline and EBITDA margin of 13%-14%. Caustic soda (Chlor-Alkali) business shows strong performance with expected EBITDA of 16%-18%, contributing to overall margin improvement. Dye intermediates division is recovering from past slowdowns, expected to deliver more than 10% EBITDA on average in the coming years. Overall EBITDA margin anticipated to improve to around 12%-13% as benzene derivatives scale up alongside stable Chlor-Alkali and improving dye interme

IN US

Sale is live|00:00:00left today

Bodal Chemicals LtdQ3 FY24Chemicals & Petrochemicals

Bodal Chemicals Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹66.3P/E: 30.4Market Cap: ₹921 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Benzene derivatives project expected to contribute significantly from Q4 FY25, with revenue of ~Rs. 320 crore at 13%-14% EBITDA once at maximum capacity.
→Production volume for benzene derivatives targeted to reach over 50% utilization by January FY26, ramping up further thereafter.
→Dye intermediates division showing volume growth and better realizations; expected to deliver improved performance going forward.
→Chlor-Alkali business anticipating further volume growth driven by increased chlorine consumption; prices improving.
→Overall company revenue growth of 27% YoY in H1 FY25, led by volume improvement especially in intermediates.
→Dye stuff and dye intermediates businesses expected to maintain or improve EBITDA margins above 10% in medium term.
→Incentive approvals and government support expected to boost business post FY25 Q1.
→Company optimistic about achieving 12%-13% EBITDA margin with contributions from benzene derivatives and Chlor Alkali segments.

Margin guidance

Category 1

→Benzene derivatives project is expected to significantly contribute starting Q4 FY25, with full ramp-up by FY26, targeting Rs. 320 crores topline and EBITDA margin of 13%-14%.
→Caustic soda (Chlor-Alkali) business shows strong performance with expected EBITDA of 16%-18%, contributing to overall margin improvement.
→Dye intermediates division is recovering from past slowdowns, expected to deliver more than 10% EBITDA on average in the coming years.
→Overall EBITDA margin anticipated to improve to around 12%-13% as benzene derivatives scale up alongside stable Chlor-Alkali and improving dye intermediate segments.
→Company expects a turnaround in profitability with increased volume and capacity utilization in dye intermediates, caustic soda, and benzene derivatives by FY26.
→Incentives from Punjab government are awaited but expected to positively impact cash flow from Q1 next year.
→Net profit growth is expected alongside improved operational efficiencies and rising top line driven by new product contributions and capacity ramp-up.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript provided does not mention any current or planned fundraising through debt or equity.
→There is no discussion or indication from management about raising funds via capital markets or loans.
→The focus of the call was primarily on operational performance, project updates (benzene derivatives), government incentives, and financial results.
→No mention of new fundraising activities or plans to raise capital was made during the Q&A or management commentary.
→The management discussed interest and depreciation costs related to the benzene derivatives project, but no new financing announcements were noted.

Order book

Yes

The transcript does not provide explicit details on the current or expected order book or pending orders for Bodal Chemicals Limited. However, relevant insights include: - The benzene derivatives project is ramping up, with expectations to reach about 30% capacity utilization in December 2024 and over 50% utilization by January 2025. - Q4 FY25 and Q1 FY26 are expected to be optimal periods for benzene derivatives revenue growth. - The dye intermediates division is experiencing better volumes and realizations with improved demand. - Chlor-Alkali business expects further volume growth due to better chlorine consumption by surrounding units. - The demand environment facing dyestuff is still affected by political disturbances in Bangladesh, impacting textiles. - Overall revenue growth is being driven by volume improvements, especially in dye intermediates. No specific numeric order book or pending order values were disclosed.

Capex plans

Yes

→The company has invested in the Saykha Greenfield benzene downstream project, a strategic expansion into specialty chemicals beyond its core dye stuff and dye intermediates business.
→This Saykha project recently achieved required quality norms and is in the process of obtaining customer certifications, especially targeting the pharmaceutical industry.
→Production and revenue contribution from this benzene derivatives project is expected to ramp up significantly starting Q4 FY25, with major volume increases thereafter.
→Interest and depreciation related to this project increased overheads, indicating ongoing capital investment impact.
→Management anticipates reaching maximum capacity utilization in benzene derivatives by Q4 FY25 or Q1 FY26, implying near-term capital utilization.
→No explicit mention of new upcoming capex projects beyond Saykha was disclosed in the call transcript.

How does Bodal Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Bodal Chemicals Ltd

Rev 3Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Bodal Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio